{"id":828122,"date":"2025-03-20T11:09:58","date_gmt":"2025-03-20T15:09:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/heng-ren-partners-demands-sinovac-distribute-8-9-billion-in-cash-to-its-shareholders-and-cause-reinstatement-of-trading\/"},"modified":"2025-03-20T11:09:58","modified_gmt":"2025-03-20T15:09:58","slug":"heng-ren-partners-demands-sinovac-distribute-8-9-billion-in-cash-to-its-shareholders-and-cause-reinstatement-of-trading","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/heng-ren-partners-demands-sinovac-distribute-8-9-billion-in-cash-to-its-shareholders-and-cause-reinstatement-of-trading\/","title":{"rendered":"Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n BOSTON<\/span>
\n <\/span>, March 20, 2025<\/span><\/span> \/PRNewswire\/ — Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac”) shareholder Heng Ren Partners, LLC funds (“Heng Ren”) today sent an open letter to Sinovac’s shareholders outlining the significant and decisive action that Sinovac’s Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng Ren demands that\u00a0Sinovac’s Board of Directors announce a distribution of $8.9 billion<\/span> in cash to its shareholders and cause the resumption of trading of the Company’s shares.<\/p>\n

The full text of the letter follows:<\/p>\n

\n March 20, 2025<\/span>\n <\/p>\n

Dear Fellow Sinovac Shareholders:<\/p>\n

Like you, we are shareholders in Sinovac Biotech Ltd. (“Sinovac” or the “Company”). \u00a0Heng Ren Partners, LLC (“Heng Ren”) manages funds that have held Sinovac shares since 2018.\u00a0 Heng Ren has long believed in the Company’s business and its potential, and Heng Ren’s conviction was borne out by the Company’s incredible success with the CoronaVac vaccine.\u00a0 In 2019, before the COVID-19 pandemic, the Company’s revenues were $246 million<\/span> with income of $39.8 million<\/span>.\u00a0 By 2021, revenue soared to more than $19 billion<\/i><\/b> with profits of $8.5 billion<\/i><\/b>.\u00a0 That incredible increase in profits and value should have been shared with us\u2014Sinovac’s shareholders and owners.\u00a0 It was not.<\/p>\n

Unfortunately, the Company did not share its meteoric success with the shareholders.\u00a0 Despite raking in massive amounts of cash\u2014Sinovac has been sitting on more than $10 billion<\/span> in net cash and cash equivalents for more than three years\u2014the Company did not make a single distribution to shareholders.\u00a0 Instead, it appears that Sinovac subsidiaries distributed billions of dollars to other entities while Sinovac common equity shareholders got nothing.\u00a0 Furthermore, litigation resulted in the suspension of Sinovac trading on NASDAQ for more than six years, preventing shareholders from trading during the Company’s massive transformation.\u00a0 That trading suspension continues through today.\u00a0 In short, shareholders were handcuffed from selling their shares at the peak of the Company’s success and the Company failed to make any distributions.<\/p>\n

On January 16, 2025<\/span>, Sinovac announced that the litigation was resolved and on February 28<\/span>, Sinovac announced that a new board of directors was appointed.\u00a0 The Company also announced that the new board was committed to achieving the resumption of trading.\u00a0 But more than three weeks have passed, and the new board has not communicated to shareholders any concrete steps or timeline.\u00a0 More importantly, the Board has not told us, the shareholders, when it will distribute the billions of dollars of hoarded cash to us, the shareholders, its rightful owners.<\/p>\n

Heng Ren calls for Sinovac’s Board to take decisive and immediate action.\u00a0 Specifically, Heng Ren has identified the following acts that the Board must take:<\/p>\n

1.\u00a0 Distribute Cash<\/u><\/b>.\u00a0 The Board should distribute $8.9 billion<\/span> of the Company’s approximately $10.3 billion<\/span> in net cash and short-term investments<\/i><\/b>to all shareholders<\/i><\/b>, with a record date for such distribution that is prior to the resumption of trading.<\/p>\n